|
RALGAPA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.75170014446746E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63900000016426E-07 |
| Normal-vs-Stage2 |
4.403300E-04 |
| Normal-vs-Stage3 |
1.64490000509332E-08 |
| Normal-vs-Stage4 |
1.0469000000235E-08 |
| Stage1-vs-Stage2 |
8.823400E-01 |
| Stage1-vs-Stage3 |
5.198300E-02 |
| Stage1-vs-Stage4 |
2.274000E-02 |
| Stage2-vs-Stage3 |
2.093800E-01 |
| Stage2-vs-Stage4 |
1.136770E-01 |
| Stage3-vs-Stage4 |
5.841400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.91240023816874E-10 |
| Normal-vs-AfricanAmerican |
4.156300E-03 |
| Normal-vs-Asian |
1.59882999999361E-05 |
| Caucasian-vs-AfricanAmerican |
3.334200E-01 |
| Caucasian-vs-Asian |
9.912200E-01 |
| AfricanAmerican-vs-Asian |
3.965600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.49510453701419E-11 |
| Normal-vs-Female |
2.41990000260373E-08 |
| Male-vs-Female |
3.249600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.4393000000188E-06 |
| Normal-vs-Age(41-60Yrs) |
2.47609999171061E-09 |
| Normal-vs-Age(61-80Yrs) |
2.90360000487766E-08 |
| Normal-vs-Age(81-100Yrs) |
2.482500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.501180E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.318200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.648000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.853000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.564000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.275400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.840200E-02 |
| Classical-VS-Follicular |
4.098200E-01 |
| Classical-VS-Other |
1.421390E-03 |
| Classical-VS-Normal |
2.50760001652139E-09 |
| Tall-VS-Follicular |
2.280200E-02 |
| Tall-VS-Other |
1.631390E-01 |
| Tall-VS-Normal |
4.2919999998503E-08 |
| Follicular-VS-Other |
4.553400E-04 |
| Follicular-VS-Normal |
2.646300E-04 |
| Other-VS-Normal |
2.66699999862396E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.22659999934882E-08 |
| Normal-vs-N1 |
2.20419999996668E-06 |
| N0-vs-N1 |
5.407800E-01 |
|
|
